Saturday, February 9, 2019
Program is subject to change

7:00 am	Registration and Continental Breakfast
7:50	Welcome and Overview / Pre-Program Test Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD
	Session I: Aging, Disease Pathogenesis, and Imaging Moderators: Philip J. Rosenfeld, MD, PhD and Zohar Yehoshua, MD, MHA
8:00	Metabolic Networks and the RPE-Photoreceptor Ecosystem in Aging and Degeneration Philip Luthert, MBBS
8:08	Ultrahigh Speed OCTA for Assessing Choricapillaris Flow Impairment James G. Fujimoto, PhD
8:16	Challenges in Imaging the Choriocapillaris Richard F. Spaide, MD
8:24	Choriocapillaris Quantification with Phansalkar's Local Thresholding: Do's and Don'ts Zhongdi Chu, PhD
8:32	Choriocapillaris in Myopia SriniVas R. Sadda, MD
8:40	Choroidal Vessel Imaging and Quantification Ruikang (Ricky) Wang, PhD
8:48	The Choroid in AMD: Connecting the Dots Philip J. Rosenfeld, MD, PhD
8:56	Deep Learning and Reticular Pseudodrusen Emily Y. Chew, MD
	Session II: Retinal Diseases and Functional Endpoints Moderators: Thomas A. Albini, MD and Jorge A. Fortun, MD
9:04	MacTel2 as a “Serine/Ceramide-Opathy” Martin Friedlander, MD, PhD
9:12	Epidemiology of Common Retinal Diseases in Retina Practices in the United States Andrew A. Moshfeghi, MD, MBA
9:20	Functional Imaging of Mitochondria in Retinal Diseases Rishi P. Singh, MD
9:28	Novel Analytics to Examine Impact of Fluctuations in Retinal Thickness on Visual Outcomes Usha Chakravarthy, MD
9:36	Drusen and Retinal Diseases Lawrence A. Yannuzzi, MD
9:44	Integrating Microperimetry into Clinical Trials of Nonexudative AMD Nadia Waheed, MD
9:52	Rod-and-Cone-Mediated Vision in Eyes with Hyperreflective Foci: An Outcome Measure for Oil Spill Trials? Christine A. Curcio, PhD
10:00	Normal and Low Luminance Quantitative Contrast Sensitivity: A Novel Functional Endpoint for Rapid Measurement of Spatial Contrast Sensitivity Functions in Dry AMD Karl G. Csaky, MD, PhD
	Session III: AMD II Moderators: Philip J. Rosenfeld, MD, PhD and Raquel Goldhardt, MD
10:08	Retina Trends – A VC’s Perspective Emmett T. Cunningham, Jr., MD, PhD, MPH
10:16	Update in Hemera’s Gene Therapy Programs Jay S. Duker, MD
10:24	Kamuvudines for AMD: The Saga Continues Jayakrishna Ambati, MD
10:32	Phase 1 Results of a Systemic Antisense Inhibitor of Complement Factor B for Geographic Atrophy Sunil S. Patel, MD, PhD
10:40	Update on FHTR2163 (anti-HtrA1) for Dry AMD Vrinda Hershberger, MD, PhD
10:48	Update on Elamipretide for the Treatment of AMD Scott W. Cousins, MD
10:56	Phase 2 Study Results of Risuteganib in Dry AMD Peter K. Kaiser, MD
11:04	Risuteganib for the Treatment of Dry AMD: Structure/Function Correlations Glenn J. Jaffe, MD
11:12	Update on Brimonidine Intravitreal Implant for Dry AMD Ryan Rich, MD
11:20	C3 inhibition in Geographic Atrophy Cedric G. Francois, MD, PhD
	Session IV: AMD III Moderators: Harry W. Flynn, Jr., MD and Luis J. Haddock, MD
11:28	PROCON Year 2 Results Jeffrey S. Heier, MD
11:36	Non-Neovascular Exudative Age Related Macular Degeneration: How to Unmask the Masquerader David Sarraf, MD
11:44	Update on Stem Cell Therapies for AMD Amir H. Kashani, MD, PhD
11:52	Unregulated Stem Cells for Ocular Disease: What Happened after the NEJM Publication Thomas A. Albini, MD
12:00pm	Retinal Implants: Where Are We Now? Jean-François Korobelnik, MD
12:08	Advanced Retinal Implants Mark S. Humayun, MD, PhD
12:16	Lunch
	Session V: Macular Neovasculation in AMD and PCV Moderators: Philip J. Rosenfeld, MD, PhD and Luis J. Haddock, MD
1:16	The Importance of MNV Type Classification in the Interpretation of the Results of Clinical Trials Giovanni Staurenghi, MD
1:24	Detection of Non-Exudative Subclinical MNV in AMD from Structural OCT Scans Using Deep Learning Aaron Y. Lee, MD
1:32	AI Based Fluid Quantification on Serial OCT Images from a Patient Self-operated Home OCT Device Anat Loewenstein, MD
1:40	Automated Volumetric Assessment of Subclinical Non-Exudative MNV Using SS-OCTA Luis de Sisternes, PhD
1:48	Rotational 3D OCTA Giuseppe Querques, MD, PhD
1:56	Diagnosis of PCV Using SS-OCTA Hiroko Terasaki, MD, PhD
2:04	Volume Rendering of OCTA in PCV K. Bailey Freund, MD
2:12	A Comparison Study of Polypoidal Choroidal Vasculopathy Imaged with ICGA and SS-OCTA Seung-Young Yu, MD
2:20	Longitudinal Changes in Subclinical PCV Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI
2:28	Longitudinal Observations of PCV Using SS-OCTA Fenghua Wang, MD
	Session VI: Treatments for Neovasculation in AMD and ROP Moderators: Thomas A. Albini, MD and Ninel Z. Gregori, MD
2:36	Immunology of Gene Therapy Janet L. Davis, MD
2:44	Phase 1 study of Intravitreal Gene Therapy with DVM-022 for Neovascular AMD (OPTIC Trial) David S. Boyer, MD
2:52	RGX-314 Gene Therapy for wAMD and Diabetic Retinopathy Jeffrey S. Heier, MD
3:00	Treatment of Newly Diagnosed and Treatment Resistant Neovascular AMD with the Oral CCR3 Inhibitor ALK4290 Michael W. Stewart, MD
3:08	Results of the Phase I/II SUSHI Study of Intravitreal RBM-007 in Exudative AMD Quan Dong Nguyen, MD, MSc
3:16	Update on Phase 1b and Phase 2 Studies of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate with Potential for Extended Durability in Wet AMD Diana V. Do, MD
3:24	Results of the Opthea OPT-302 Phase 2b Study: Combined VEGF-C / VEGF-D Suppression for nvAMD Pravin U. Dugel, MD
3:32	Phase 2 LADDER Trial Using the Port Delivery System with Ranibizumab: End of Study, Long-term Follow-up Results Carl D. Regillo, MD
3:40	Faricimab Update Karl G. Csaky, MD, PhD
3:48	Brolucizumab Update Lawrence J. Singerman, MD
3:56	Do We Need More VEGF Blockade?- The Rationale for a Clinical Trial Testing High-Dose Aflibercept David M. Brown, MD
4:04	Update on ROP and Anti-VEGF Clinical Trials Darius M. Moshfeghi, MD
	Session VII: Diabetes Moderators: Harry W. Flynn, Jr. MD and Justin H. Townsend, MD
4:12	Effect of Industry Funding on Abstract Bias in the Literature for Intravitreal Pharmacotherapy for Retinal Vascular Disease Jayanth Sridhar, MD
4:20	DRCR Retina Network Trials and Real World Experience Jennifer Sun, MD
4:28	Diabetic Retinopathy: Is a New Classification on the Way? Lee M. Jampol, MD
4:36	Artificial Intelligence Assisted Approaches for Diabetic Retinopathy Screening Michael S. Ip, MD
4:44	The Pattern and Density of Retinal Capillary Plexuses from the Fovea to the Periphery Using SS-OCTA Ramin Tadayoni, MD, PhD
4:52	Wide-field SS-OCTA is Better than FA in Detecting Capillary Dropout, Neovascularization and IRMA in Diabetic Retinopathy Toshinori Murata, MD, PhD
5:00	Widefield SS-OCTA in Diabetic Retinopathy Harry W. Flynn, Jr. MD
5:08	Development of DME in Fellow Eyes from VIVID/VISTA Dilsher Dhoot, MD
5:16	Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 2-Year Outcomes of the Phase 3 PANORAMA Study Charles C. Wykoff, MD, PhD
	Session VIII: Diabetes, Uveitis, and Retinal Degenerations Moderator: Philip J. Rosenfeld, MD, PhD and Thomas A. Albini, MD
5:24	A Novel Implant for Delivering Low-Dose Extended Release Dexamethasone for Macular Edema Elias Reichel, MD
5:32	The Oculis OCS-01 Phase 1/2 Study: An Effective Topical Therapeutic for DME Pravin U. Dugel, MD
5:40	Front-line Local Therapies for Uveitis: From Clinical Trials to Practice Steven Yeh, MD
5:48	Treatments and Clinical Trials in Inherited Retinal Degenerations Byron L. Lam, MD
5:56	Phase 2 1-year Results of the JCyte Trial for Retinitis Pigmentosa David S. Boyer, MD
6:04	Results of a Clinical Trial Investigating N-acetylcysteine in Retinitis Pigmentosa Peter A. Campochiaro, MD
6:12	Post-Program Test and Closing Remarks
6:20	Adjourn/Cocktail Reception